Table 4 Comparison of incremental per person cost-effectiveness results for basecase and scenario analyses.

From: Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England

Scenario Analysis	Incremental Cost	Incremental Life Years	Incremental QALYs	Incremental NMB	ICER	Probability Cost-effective
Basecase	£70.89	0.0097	0.0059	£46.42	£12,085	0.962
1a) Reduced Cancer Stage-Specific Mortality with Screening - as per Cardoso et al. 2022	−£59.50	0.0190	0.0124	£307.39	Dominant	1.000
1b) Reduced Cancer Stage-Specific Mortality with Screening – half the impact of Cardoso et al. 2022	£16.19	0.0137	0.0087	£157.61	£1863	1.000
2a) Cancer Stage Shifts with Screening Halved	£88.61	0.0079	0.0046	£4.01	£19,134	0.563
2b) % Cancer Stage Four with Screening 25% More	£71.61	0.0096	0.0058	£44.56	£12,329	0.957
2c) % Cancer Stage Four with Screening 25% Less	£70.17	0.0098	0.0059	£48.31	£11,845	0.967
3a) Cancer Metastatic Treatment Costs Halved	£84.25	0.0097	0.0059	£33.07	£14,362	0.922
3b) Metastatic Treatment Costs Halved for all Cancers Apart from Kidney Cancer	£74.45	0.0097	0.0059	£42.86	£12,692	Between 0.922 and 0.962^a
3c) Metastatic Treatment Costs Doubled	£44.18	0.0097	0.0059	£73.14	£7531	0.987
3 d) Metastatic Treatment Costs Doubled for all Cancers Apart from Kidney Cancer	£63.77	0.0097	0.0059	£53.55	£10,871	Between 0.962 and 0.987^a
3e) All Cancer Treatment Costs Halved	£77.21	0.0097	0.0059	£40.11	£13,162	0.963
4a) Kidney Cancer Prevalence Doubled	£52.35	0.0110	0.0066	£80.26	£7895	0.996
4b) Kidney Cancer Prevalence Halved	£80.16	0.0090	0.0055	£29.51	£14,619	0.878
4c) All Cancer Prevalence Doubled	£45.65	0.0107	0.0062	£78.55	£7351	0.968
4 d) All Cancer Prevalence Halved	£83.51	0.0092	0.0057	£30.36	£14,667	0.937
5) Utility Decrement Included for Secondary Findings	£70.89	0.0097	0.0043	£15.16	£16,476	0.702
6) YKST Population Age Distribution (55–81)	£106.50	0.0084	0.0048	−£9.63	£21,989	0.366
7a) Discount Rates for Costs and QALYs 1.5%	£61.06	0.0132	0.0084	£106.35	£7295	1.000
7b) Discount Rates for Costs and QALYs 5%	£77.73	0.0077	0.0045	£11.46	£17,430	0.681
8a) No AAA Findings Included in Model	£21.49	0.0010	−0.0004	−£30.05	Dominated	0.087
8b) Only AAA Findings Included in Model	£71.08	0.0087	0.0055	£39.35	£12,873	0.999
8c) Only Kidney Findings Included in Model	£25.26	0.0013	−0.00001	−£25.42	Dominated	0.015

Incremental results that are cost-saving or dominant compared to current care are highlighted in bold text, whilst incremental results that lose QALYs or life years, or that are not cost-effective compared to current care (assuming a willingness to pay threshold of £20,000 per QALY), are highlighted in italic text.
QALY Quality-adjusted life-year, INMB Incremental net monetary benefit assuming a willingness to pay threshold of £20,000/QALY, ICER Incremental cost-effectiveness ratio, YKST Yorkshire Kidney Screening Trial.
^aNot possible to estimate uncertainty more precisely due to way in which sensitivity analysis results calculated.

Back to article page

Table 4 Comparison of incremental per person cost-effectiveness results for basecase and scenario analyses.

Search

Quick links